Hematology / Oncology @Point of Care Podcasts

@Point of Care

Non-Small Cell Lung Cancer

Acute Myeloid Leukemia

CAR T-Cell Therapy

Biomarker Testing

Hr-Positive Breast Cancer

Relapsed Refractory Multiple Myeloma

Antibody Drug Conjugates

Breast Cancer

Trop2

FLT3 Mutations

Polycythemia Vera

Liquid Biopsies

Trop2-Directed Adcs

Astrazeneca

Genomic Testing

Multiple Myeloma

Clinical Trials

Essential Thrombocythemia

HER3

Biomarkers

Our @Point of Care Hematology & Oncology Podcasts have healthcare experts discussing and providing information related to oncology diagnosis, treatment, management, and other important information.

16 ratings

Publishes	Daily	Episodes	89	Founded	6 years ago
Number of Listeners		Category	Health & Fitness

Listen to this Podcast

Guests Host Charts Talking Points

Latest Episodes

S28:E2 – Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS

In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS they review the clinical trial and real-world evidence on the efficacy and safety of currently available therapies for patients with lower-risk myelodysplastic syndrome (... more

24 Apr 2026 • 30 min

S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS

In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS explore dose escalation strategies for the erythroid maturation agent (EMA), luspatercept, in patients with lower-risk myelodysplastic syndrome (LR-MDS). Their engaging d... more

24 Apr 2026 • 23 min

S27:E3 – Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs

In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterat... more

15 Jan 2026 • 30 min

S27:E2 – TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib

In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising targ... more

15 Jan 2026 • 28 min

Key Facts

Accepts Sponsors

Contact Information

Podcast Host

Number of Listeners

Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

CME in Minutes: Education in Oncology & HematologyAnswers in CME

Recent Guests

Andrew Kuykendall

Assistant Member, Moffitt Cancer Center, Department of Malignant Hematology

Moffitt Cancer Center

Episode: S28:E2 – Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS

Sangeetha Venugopal

Assistant Professor of Clinical Medicine, Division of Hematology

University of Miami

Episode: S28:E2 – Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS

Dr. Andrew Kuykendall

Assistant Member of the Moffitt Cancer Center, Department of Malignant Hematology, Tampa, Florida

Moffitt Cancer Center

Episode: S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS

Dr. Sangeetha Venugopal

Assistant Professor of Clinical Medicine, Division of Hematology, University of Miami

University of Miami

Episode: S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS

Dr. Charu Aggarwal

Leslie M. Heisler Professor of Medicine and Section Chief of Thoracic and Head and Neck Cancer at the Abramson Cancer Center.

Abramson Cancer Center

Episode: S27:E1 – HER2-Directed ADCs in Advanced NSCLC

Beth Sandy

Nurse Practitioner at the Abramson Cancer Center.

Abramson Cancer Center

Episode: S27:E1 – HER2-Directed ADCs in Advanced NSCLC

Joseph Mikhael

Professor of Clinical Genomics and Therapeutics

Translational Genomics Research Institute at the City of Hope Cancer Center

Episode: S24:E2 – Identifying Patients for CAR T-Cell Therapy in Earlier Treatment Lines for RRMM

Krina Patel

Associate Professor in the Department of Lymphoma and Myeloma

MD Anderson Cancer Center

Episode: S24:E2 – Identifying Patients for CAR T-Cell Therapy in Earlier Treatment Lines for RRMM

Joyce O'Shaughnessy

Celebrating Women Chair in Breast Cancer Research at Baylor University Medical Center

Baylor University Medical Center

Episode: S23:E2 – Mapping the Pathway in Metastatic Breast Cancer

Host

Candace Hoffman

Host of Morning Commute; involved with Projects in Knowledge, powered by Kaplan; appears across Hematology/Oncology content

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts

#158

Finland/Health & Fitness

Talking Points

Recent interactions between the hosts and their guests.

S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS

Q: How do you approach dose titration for luspatercept in practice, and what are the practical thresholds for escalation?

Start at 1 mg/kg every three weeks; if transfusion-free status is not achieved or if hemoglobin response is inadequate, escalate to 1.33 mg/kg after two consecutive doses, then to 1.75 mg/kg after two more consecutive doses, with a maximum of 1.75 mg/kg and escalations not being made more often than every six weeks.

S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS

Q: Before we dive into the details, can you just give us a brief overview of low-risk MDS and available therapies?

Low-risk MDS is characterized by ineffective hematopoiesis with anemia as a common symptom; treatment focuses on symptom control and improving hematological parameters, using agents like ESAs, lenalidomide in DEL5Q, and newer options such as luspatercept and imetelstat, which target different mechanisms to reduce transfusion burden.

S22:E2 – Advances in TROP2-directed ADCs for Non-Small Cell Lung Cancer: First-Line and Combination Therapies

Q: Can you speak for a moment about one, I mean, that is, I think, fairly straightforward to then have that be an endpoint based upon the data that we have?

It will be interesting to see if the QCS NMR testing extends its utility beyond non-squamous, non-actionable genomic populations.

S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies

Q: How do you counsel patients about potential adverse events from TROP2-targeting therapies?

I explain to patients that this therapy is a hybrid between targeted therapy and chemotherapy, emphasizing the diverse range of possible side effects.

S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies

Q: What are some treatment-related adverse events associated with the antibody drug conjugates?

Common adverse events include mucositis, interstitial lung disease, alopecia, nausea, vomiting, leukopenia, and thrombocytopenia.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

The show features in-depth discussions with hematology and oncology clinicians, researchers, and advanced practice providers who break down complex cancer therapies, diagnostics, and emerging treatment strategies. Episodes frequently center on targeted therapies, cellular and antibody-drug conjugate approaches, and evolving treatment paradigms across blood cancers and solid tumors, with practical takeaways for dosing, sequencing, and patient selection. A standout pattern is the mix of real-world experience and trial data interpretation, often highlighting translational insights, biomarker testing, and the evolving role of innovative therapies (e.g., CAR T cells, ADCs, and mutation-targeted agents) in shaping frontline and subsequent-line ca... more

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. CME in Minutes: Education in Oncology & Hematology

How many episodes of this podcast are there?

this podcast launched 6 years ago and published 89 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Andrew Kuykendall
2. Sangeetha Venugopal
3. Dr. Andrew Kuykendall
4. Dr. Sangeetha Venugopal
5. Dr. Charu Aggarwal
6. Beth Sandy
7. Joseph Mikhael
8. Krina Patel

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.

Try it free for 7 days